000			02074nam a2200433 i 4500
999			_c273259 _d273259
001			on1045067223
003			OCoLC
005			20180815142001.0
007			he bmb024bbca
008			180719s2018 dcuab bb f000 0 eng c
040			_aPUCPR _beng _erda _cGPO _dMvI
042			_apcc
043			_an-us---
074			_a1016-B (MF)
086	0		_aY 4.G 74/7:115-35
088			_aSerial no. 115-35 (United States. Congress. House. Committee on Oversight and Government Reform)
099			_aY 4.G 74/7:115-35
110	1		_aUnited States. _bCongress. _bHouse. _bCommittee on Oversight and Government Reform,
245	1	0	_aOffice of National Drug Control Policy : _breauthorization in the 115th Congress : hearing before the Committee on Oversight and Government Reform, House of Representatives, One Hundred Fifteenth Congress, first session, July 26, 2017.
264		1	_aWashington : _bU.S. Government Publishing Office, _c2018.
300			_aiii, 88 pages : _billustrations, map ; _c24 cm
336			_btxt
337			_bh _2rdamedia
338			_bhe _2rdacarrier
500			_a"Serial no. 115-35."
500			_aShipping list no.: 2018-0099-M.
500			_aCRDP Program record.
504			_aIncludes bibliographical references.
533			_aMicrofiche. _b[Washington, D.C.] : _cU.S. Government Printing Office, _d[2018] _e1 microfiche : negative.
776	0	8	_iPrint version: _aUnited States. Congress. House. Committee on Oversight and Government Reform. _tOffice of National Drug Control Policy _w(DLC) 2017393116 _w(OCoLC)1024318685
776	0	8	_iOnline version: _aUnited States. Congress. House. Committee on Oversight and Government Reform. _tOffice of National Drug Control Policy _w(OCoLC)1023431808
050		4	_aKF27 _b.O94 2017k
610	1	0	_aUnited States. _bOffice of National Drug Control Policy.
650		0	_aDrug control _zUnited States.
650		0	_aOpioid abuse _zUnited States.
650		0	_aDrug abuse _xTreatment _zUnited States.
655		7	_aLegislative hearings. _2lcgft
942			_2sudocs _c8